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In£ammation is accompanied by activation of the coa-
gulation cascade, manifested by thrombosis and ¢brin
generation.Whereas endothelial cells normally provide
a nonthrombogenic surface, in£ammatory mediators
may induce the expression of tissue factor, rendering
their surface thrombogenic. In order to de¢ne the me-
chanisms regulating the expression of tissue factor in
the skin microvasculature, we examined tissue factor
expression in human dermal microvascular endothelial
cells. Quiescent human dermal microvascular endothe-
lial cells did not constitutively express tissue factor pro-
tein, but were induced to express tissue factor by
treatment with tumor necrosis factor-a in a time- and
concentration-dependent fashion. Increased expression
of tissue factor protein was accompanied by increases
in steady-state mRNA levels. Tumor necrosis factor-a
treatment resulted in increased expression of tissue fac-
tor heterogeneous nuclear RNA without changes in
mRNA stability, suggesting that increased mRNAwas
mediated primarily via increased tissue factor gene
transcription. In order to de¢ne the pathways regulat-
ing tissue factor induction, we examined the e¡ects of
MG-132, an inhibitor of nuclear factor-jB activation,
PD98059, an inhibitor of MEK1 action, and SB203580,
an inhibitor of activated p38 activity. MG132 only par-
tially blocked tumor necrosis factor-a-induced tissue
factor protein expression, despite an almost complete
inhibition of tumor necrosis factor-a-induced E-selec-
tin expression. In contrast, SB203580, almost completely
inhibited tumor necrosis factor-a-induced tissue factor
expression but inhibition of MEK1 by PD98059 had a
minimal e¡ect on tumor necrosis factor-a-mediated
tissue factor induction in human dermal microvascular
endothelial cells. Both SB203580 and MG132 treatment
inhibited tumor necrosis factor-a-mediated increases
in tissue factor mRNA and tissue factor gene trans-
cription as measured by expression of tissue factor
heterogeneous nuclear RNA.These data support a tran-
scriptional role for both nuclear factor-jB and p38
mitogen-activated protein kinase, but not MEK1 in tis-
sue factor gene expression in human dermal microvas-
cular endothelial cells. Key words: cytokine, endothelium/
mitogenactivated protein kinase/thromboplastin/tumor ne-
crosis factor. J Invest Dermatol 120:489 ^494, 2003
T
he vascular endothelium is a dynamic interface, nor-
mally providing a nonadhesive, nonthrombogenic
surface for blood constituents, however, in response
to proin£ammatory stimuli from cytokines and bac-
terial products, or in response to vascular wall shear
stress, induction of adhesion molecules and the expression of en-
dothelial cell surface procoagulant proteins may occur (Semeraro
and Colucci, 1997; Mantovani et al, 1997). Central to the conver-
sion of normal endothelium to a procoagulant surface is the
induction of tissue factor (TF) on endothelial cells. TF is a
transmembrane protein and a member of the class II cytokine
and hematopoietic growth factor receptor family. It is located on
the surface of a number of cell types, primarily monocytes, vas-
cular endothelial cells, and smooth muscle cells.
The extracellular domain of TF serves as a receptor for acti-
vated factor VII (VIIa) (Morrissey, 2001). In the absence of TF,
factor VIIa exhibits very poor activity towards its substrates,
factors IX and X. Once bound to TF, however, this complex ra-
pidly initiates the coagulation cascade by catalyzing the conver-
sion of factors IX and X to factors IXa and Xa. Under normal
circumstances, circulating factor VII is not exposed to TF.When
the integrity of the vasculature is breached or endothelial cells are
induced to express cell surface TF, however,TF may then interact
with factor VIIa and initiate blood coagulation (Semeraro and
Colucci, 1997).
TF is normally undetectable on endothelial cells in vivo; how-
ever, in£ammatory mediators and angiogenic factors, such as vas-
cular endothelial growth factor may induce the expression of TF
on the surface of endothelial cells rendering their surface throm-
bogenic (Osterud and Bjorklid, 2001). The cell surface expression
of TF has long been implicated in the pathophysiology of acute
and chronic in£ammation, the thromboembolic complications of
atherosclerosis and vascular injury and repair (Taubman et al,
1997). In addition, in endothelial cells,TF expression has been re-
ported in vivo in association with neoplastic disease and cytokine
activation in association with sepsis (Semeraro and Colucci, 1997).
This inappropriate expression of TF may be responsible for
thrombotic disorders and ¢brin deposition as seen in dissemi-
nated intravascular coagulation and thromboembolic disease.
Despite the fact that most in vivo TF expression has been
noted in the microvasculature (Contrino et al, 1994, 1996), most
in vitro endothelial studies have been done in large vessel derived
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endothelial cells (Parry and Mackman, 1995; Mackman, 1996;
Camera et al, 1999; Holzmuller et al, 1999; Mechtcheriakova et al,
1999, 2001; Holschermann et al, 2001). Studies of TF gene regula-
tion done in human microvascular endothelial cells are limited
(Zhang et al, 1999; Yang and Loscalzo, 2000).We therefore exam-
ined the regulation of TF protein and gene expression in human
dermal microvascular endothelial cells (HDMEC), and the in£u-
ence of modulators of de¢ned signaling pathways.
MATERIALS AND METHODS
Cell culture Primary cultures of HDMEC derived from neonatal
foreskins (Swerlick et al, 1992) and human umbilical vein endothelial cell
(HUVEC) were obtained from Emory University Skin Diseases
Research Center and used at passage number 4^7. Cells were cultured in
£asks coated with 0.1% gelatin using MCDB131 media (Mediatech,
Herndon, VA) supplemented with 10% heat-inactivated fetal bovine serum
(FBS) (Hyclone, Logan, UT), 2 mM L-glutamine and 1antibiotic/anti-
mycotic solution (Mediatech), 4 mg per ml hydrocortisone and 250 mg
per ml dibutyrl cyclic adenosine monophosphate (Sigma, St Louis,
MO). HUVEC were cultured in medium 199 supplemented with 20%
heat-inactivated FBS, 1 U per ml heparin, 50 mg per ml Endothelial
Mitogen (Biomedical Technologies no. BT-203), 2 mM L-glutamine and
1antibiotic/anti-mycotic solution (Mediatech). In all experiments cells
were rendered quiescent by replacing the media of 2 d postcon£uent
£asks with starving media containing 1% FBS without dibutyrl cyclic
adenosine monophosphate 24 h prior to stimulation.
Reagents the inhibitors MG132, SB203580, SB202190, and PD98059
were purchased from Calbiochem (San Diego, CA). Tumor necrosis factor
(TNF)-a was purchased from R&D Systems (Minneapolis, MN).
Actinomycin D and cycloheximide were purchased from Sigma. The anti-
TF monoclonal antibody, 4508, was purchased from American
Diagnostica, Inc. (Greenwich, CT). The E-selectin monoclonal antibody
was generated from a hybridoma developed by Elizabeth Wayner and
Greg Vercellotti and was obtained from the Developmental Studies
Hybridoma Bank developed under the auspices of the NICHD and
maintained by the University of Iowa, Department of Biological Sciences
(Iowa City, IA). Rabbit polyclonal antibodies speci¢c for P44/42 mitogen-
activated protein kinase (MAPK) 1/2 (p44/42 MAPK) and phospho-P44/42
MAPK1/2 antibodies were purchased from Cell Signaling Technology
(Beverly, MA). The goat anti-mouse IgG horseradish peroxidase-conju-
gated secondary antibody was purchased from Bio-Rad (Hercules, CA).
Primers for quantitative polymerase chain reaction (PCR) for TF
mRNA (50 -CAC CGA CGA GAT TGT GAA GGA T-30 and 50 -CCC
TGC CGG GTA GGA GAA-30), TF heterogeneous nuclear RNA
(hnRNA) (Elferink and Reiners, 1996) (50 -CCC CTG GGT TGC TAT
GAG G-30 and 50 -CCT AGC AAC ACC GAG CAC TTG-30), and
podoplanin (50 -CCT GAG CTC GTG GGA GAA GA-30 and 50 -GAG
AGG TCA CCG TGG ATT CTG-30) were synthesized by the
Microchemical Facility of the Winship Cancer Center, Emory University
School of Medicine.
Cell surface enzyme-linked immunosorbent assay (ELISA) Cell
surface TF and E-selectin were measured by ELISA as described
previously (Swerlick et al (1992). Cells were plated in 96-well £at-
bottomed plates and rendered quiescent as described above. Selected wells
were pretreated with 50 mM MG-132, 10 mM SB203580, 10 mM SB202190, or
50 mM PD98059 30 min prior to stimulating with 1000 U per ml TNF-a
and 20% nonheat-inactivated serum. After 4 h, the plates were incubated
for 1 h at room temperature with 2 mg per ml anti-TF antibody or a 1 : 2
dilution of anti-E-selectin supernatant diluted in ELISA bu¡er (Hanks
bu¡er, 10% FBS). The antibody solution was removed and the plate ¢xed
with 2% formaldehyde for 15 min the plate was then washed two to three
times with ELISA bu¡er and incubated with a 1 : 500 dilution of goat anti-
mouse IgG horseradish peroxidase-conjugated secondary antibody (Bio-
Rad) for 45^60 min at room temperature. After a thorough washing with
ELISA bu¡er, the ELISA was developed using TMB substrate solution
(DAKO, Carpenteria, CA.). The reaction was stopped with 8 M sulfuric
acid and read on an ELISA microplate reader (Bio-Tek Instruments,
Winooski, VT) at OD 450 nm.Values shown represent the mean value of
wells done in quadruplicate7SD. Each experiment was done a minimum
of three times. Signi¢cance of inhibition was assessed by a paired Student t
test.
Flow cytometric analysis Cell surface expression of TF was examined
in HDMEC by £ow cytometric analysis as previously described (Swerlick
et al, 1992). Brie£y, HDMEC were stained for TF expression before and
after TNF-a (1000 U per ml) or phorbol myristate acetate (100 ng per ml)
for 4 h. Cells were trypsinized, aliquoted, pelleted, and stained with anti-
TF monoclonal antibody (American Diagnostica, Inc.) followed by FITC
conjugated goat anti-mouse IgG antibody (Caltag, Burlingame, CA). Mean
channel £uorescence was determined for each data point using a minimal
of 10,000 events.
Analysis TF mRNA and hnRNA HDMEC were rendered quiescent
as described above prior to a 2 h stimulation with 1000 U per ml TNF-a
and 20% nonheat-inactivated serum. Reverse transcription^PCR was
performed as described below. For message stability experiments, multiple
plates were left unstimulated or stimulated with 1000 U per ml TNF-a and
20% nonheat-inactivated FBS for 2 h. At this time, one plate from each
condition was harvested to determine baseline levels of message. The
remaining plates were treated with 0.5 mg actinomycin D per ml and
harvested at several points poststimulation. Reverse transcription^PCR
was performed as described below. The rate of relative decay plotted and
half-life calculated from the resulting curve.
Total RNA was isolated using Tri-Reagent (Sigma) according to the
manufacturer’s instructions. RNAwas treated with RNase-free DNase for
1 h at room temperature to remove any potential genomic DNA
contamination. DNase was inactivated at 751C for 30 min. cDNA was
then generated using the Superscript II First Strand cDNA Pre-
Ampli¢cation System (GibcoBRL, Rockville, MD) according to the
random primer protocol of the manufacturer’s instructions. Induction of
mRNA and hnRNAwere measured by real-time quantitative PCR using
the Perkin Elmer GeneAmp 5700 Sequence Detection System. PCRwas
performed using SYBR green master mix (Perkin Elmer,Wellesley, MA)
with primers optimized as recommended. Relative quantities were
calculated by the DDCt method1 normalizing for GAPDH or 18S
housekeeping genes. Data were expressed as fold increase over a
nonstimulated media control.
Western blot analysis HDMEC were made quiescent as described
above. Cells were pretreated with MG-132, PD98059, or SB203580 30 min
following stimulation with TNF (1000 U per ml  10 min). Dishes were
washed twice with ice-cold PBS, and the cells were lyzed by adding 500 ml
of the recommended lysis bu¡er (20 mM Tris, pH 7.5, 150 mM NaCl,
1 mM ethylenediamine tetraacetic acid, 1 mM ethyleneglycol-
bis-(b-aminoethylether)-N,N,N0,N0-tetraacetic acid, 2.5 mM sodium
pyrophosphate, 1 mM a-glycerol phosphate, 1 mM Na3VO4) directly to the
plate. Lysate was collected, incubated on ice for 15 min, centrifuged at
12,000 r.p.m. (2000 g) for 10 min to remove cell debris, and stored at
^ 801C. Protein was quanti¢ed using the Bio-Rad DC Protein Assay Kit.
Twenty micrograms of each extract was resolved using sodium dodecyl
sulfate^polyacrylamide gel electrophoresis on a 12% gel under reducing
conditions. The proteins were transferred to nitrocellulose for 4 h at 60 V
and were visualized with Ponceau S (Sigma) to ensure even loading. The
membranes were blocked in 5% dry milk, incubated with a 1 : 2000
dilution of rabbit polyclonal anti-p44/42 MAPK or anti-phospho-p44/42
MAPK (Cell Signaling Technology, Inc., Beverley, MA) for 1 h, followed
by horseradish peroxidase conjugated goat anti-rabbit antibody (1 : 20,000)
for 30^45 min. Protein was visualized by enhanced chemiluminescence.
Equivalent protein loading was demon-strated by reprobing blots with
rabbit anti-actin.
RESULTS
TNF-a induces expression of TF in HDMEC Unstimulated,
quiescent HDMEC expressed minimal amounts of cell surface
TF as determined by cell-based ELISA and £ow cytometric
analysis (Fig 1). Stimulation of HDMEC with TNF-a, however,
resulted in a marked upregulation of cell surface TF expression
in a concentration- and time-dependent fashion (Fig 1a,b).
Augmented cell surface expression of TF was apparent by 1 h
and maximal after 6 h. Expression was still detectable 16 h after
stimulation, but was less than 20% of maximal levels after 24 h.
In order to examine whether increases in cell surface expression
of TF were accompanied by changes in TF mRNA expression,
mRNA from HDMEC, with and without TNF-a stimulation,
1Applied Biosystems Relative Quantitation of Gene Expression: ABI
Prism 7700 Sequence Detection System: User Bulletin #2: Rev B.
(http://docs.appliedbiosystems.com/pebiodocs/04303859.pdf). December 11,
1997.
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was examined by quantitative PCR. Increases in cell surface
protein expression were accompanied by increases in steady-state
mRNA levels for TF (Fig 2a). Increases in steady-state expression
of mRNA after 4 h of TNF-a stimulation ranged from 19- to
104-fold (53.4731.8, n¼10).
The induction of TF mRNAwas rapid and was not inhibited
by cycloheximide treatment (Fig 2b), suggesting TF mRNA
induction did not require new protein synthesis; however, the
cycloheximide e¡ect is complex, with potentially competing
e¡ects on mRNA stability and gene transcription. Treatment
with cycloheximide alone actually resulted in modest increases
in TF mRNA levels and cycloheximide treatment augmented
responses to TNF-a. These data suggest that regulation of TF
mRNA levels may be a¡ected by the presence of a labile
regulatory protein, which may target TF mRNA for
degradation.
TNF-a increases HDMEC TF via a transcriptional
mechanism In order to examine whether TNF-a mediates
increase in TF expression via a transcriptional mechanism, we
examined the transcriptional activity of the TF gene using real-
time PCR measuring levels of unspliced, heterogeneous nuclear
(hnRNA) (Elferink and Reiners, 1996). Treatment of HDMEC
with TNF-a induced 10^20-fold increases in TF hnRNA. As
expression of hnRNA is short-lived due to rapid splicing to
mature RNA, expression of TF hnRNA after TNF-a
stimulation is re£ective of TNF-a-mediated TF gene
transcription. Increases were noted as early as 30 min, peaked
after 2 h, and were essentially undetectable after 8 h (Fig 2a).
Upregulation of hnRNA was completely inhibited by
pretreatment with actinomycin D (Fig 2b), thus providing
further evidence that at least part of the TNF-a-mediated
increase in steady-state TF mRNA levels was a consequence of
increased TF gene transcription. In order to determine whether
TNF-a-mediated increases in steady-state levels of TF mRNA
may also be induced via changes in mRNA stability, we
examined mRNA decay with and without TNF-a pretreatment.
TF mRNA half-life wasE 2.5 h either with or without TNF-a
pretreatment (Fig 3). These data would suggest that TNF-a
mediates increases in TF expression primarily via increased gene
TF gene expression.
TNF-a mediates TF induction via an nuclear factor (NF)-
jB, p38 MAPK-dependent mechanism In order to delineate
the signaling pathways mediatingTNF-a and serum induction of
TF, we examined the role of possible pathways downstream of
Figure1. TNF-a induces cell surface tissue factor protein in
HDMEC in a time- and concentration-dependent fashion. (A)
HDMEC were stimulated with TNF-a for 1^48 h and examined for TF
expression by cell surface ELISA as described in the Materials and Methods.
TF expression was upregulated by 4 h and peaked after 6 h of stimulation.
TF expression at 24 h is decreased to less than 20% of the maximal level
seen at 6 h. (B) HDMEC were stimulated for 4 h with TNF-a in doses
ranging from 1 to 1000 U per ml and examined for TF expression by cell
surface ELISA. Increasing doses of TNF-a resulted in increasing expression
of TF. (C) Cell surface expression of TF demonstrated by £ow cytometric
analysis: HDMEC were stained with anti-TF monoclonal antibody fol-
lowed by FITC-conjugated goat anti-mouse IgG antibody. Unstained
HDMEC (gray shaded histogram), TF expression on untreated HDMEC
(broken line), and TF expression on TNF-a treated HDMEC (black solid
line).
Figure 2. TNF-a induces increases in TF mRNA expression via a
transcriptional mechanism. (A) Total cellular RNAwas harvested from
HDMEC after stimulation with TNF-a (1000 U per ml) for periods ran-
ging from 1 to 8 h. mRNA and hnRNA was measured by quantitative
PCR as described in the Materials and Methods. Expression of both hnRNA
and mRNA are rapidly induced byTNF-a, peaking after 2 h of stimula-
tion and falling to near baseline levels by 8 h. (B) the induction of TF
mRNAwas not inhibited by cycloheximide treatment.
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TNF-a stimulation. Previous studies have implicated the
importance of transcriptional regulation of the TF gene
mediated via NF-kB and egr-1 binding element in the TF
promoter. In order to examine the potential role for NF-kB, we
utilized the proteasomal inhibitor MG132, which blocks TNF-a-
induced IkBa degradation and NF-kB nuclear translocation
(Read et al, 1995). MG132 (50 mM) only partially inhibited
TNF-a-mediated TF protein induction (Fig 4a). The average
inhibition was 58%724% (n¼ 6, po0.05). In contrast, MG-132
pretreatment completely abrogated TNF-a-mediated induction
of E-selectin (Fig 4b). This suggests that, although TNF-a-
increases of TF mRNA levels was partially dependent upon
NF-kB activation, other activation pathways are involved.
The function of other regulatory elements of theTF promoter,
such as AP-1 and egr-1 sites, have been linked to MAPK
activation (Mackman, 1996, 1997; Mechtcheriakova et al, 1999,
2001). Therefore, we next examined whether pharmacologic
blockade of speci¢c MAPK would inhibit TF induction.
Previous studies in large vessel derived HUVEC have suggested
a key role for MEK1 activation of p44/42 MAPK in TF gene
induction (Mechtcheriakova et al, 1999, 2001). In contrast to the
previous observations in HUVEC, pretreatment with the MEK1
inhibitor PD98059 (50 mM) had a minimal e¡ect on TNF-a-
mediated TF protein induction (Fig 5b). Pretreatment with
PD98059 resulted in minimal inhibition of TNF-a-mediated TF
induction 16718% (n¼ 5, p40.05). Pretreatment of HDMEC
with speci¢c inhibitors of activated p38 MAPK SB203580 (10
mM) and SB202190 (10 mM) (Davies et al, 2000), however, almost
completely inhibited TNF-a-mediated TF induction (86713%,
n¼ 5, po0.05) (Fig 5a,e), respectively. SB203580 and PD98059
pretreatment resulted in only modest inhibition of E-selectin
expression (Fig 5c,d), respectively.
Because some of our results in HDMEC were di¡erent from
what had previously been reported in HUVEC, we examined
the e¡ects of PD98059, MG-132, and SB203580 on TNF-a-
mediated TF induction in HUVEC (Fig 5f). In agreement with
previous studies demonstrating partial inhibition of TNF-a-
mediated TF induction by blockade of MEK1, we also found
that PD98059 blocked TNF-a-mediated TF induction in
HUVEC. Similarly, MG-132 also blocked TF induction by
TNF-a, and was a more e¡ective inhibitor in HUVEC than
HDMEC at the cell surface protein level. We also found that
SB203580 markedly inhibited TNF-a-mediated TF induction, a
feature common to both HDMEC and HUVEC (Fig 5f).
In order to determine whether PD98059 and SB203580
induced predicted e¡ects on P44/42 MAPK activation in treated
HDMEC, we determined the expression of phospho-p44/42
MAPK using phospho-speci¢c antibodies (Fig 5g). Cultured
HDMEC constitutively express phosphorylated P44/42 MAPK
and expression of phospho-P44/42 MAPK was increased
modestly after TNF-a stimulation. Treatment of HDMEC with
PD98059 blocked both constitutive phospho-p44/42 MAPK
expression and TNF-a-mediated increases in phospho-p44/42
MAPK. In contrast, pretreatment of HDMEC with the p38
inhibitor SB203580 did not inhibit, but slightly augmented
phospho-p44/42 MAPK expression. These data suggest that the
upregulation of TF by TNF-a in HDMEC is independent of
p44/42 MAPK activation.
In order to identify potential regulatory targets for SB203580
and MG132 e¡ects, we examined the e¡ect of these agents on
levels of TF steady-state mRNA and TF gene transcription (Fig
6). Pretreatment of HDMEC with SB203580 inhibited TNF-a-
mediated increases in TF mRNA levels that were commensurate
with inhibition of protein levels. In contrast, pretreatment with
PD98059 had no e¡ect on TNF-a-mediated increases, consistent
with observations made at the protein level (data not shown).
Pretreatment with the proteasome inhibitor MG132 blocked
TNF-a-mediated increases of TF mRNA almost as e¡ectively as
SB203580, despite having more modest e¡ects on TF cell surface
levels. Similarly, pretreatment with SB203580 or MG132, but not
Figure 3. TNF-a stimulation of HDMEC does not a¡ect TF mRNA
stability. HDMEC, with or without TNF-a pretreatment (1000 U per ml
 4 h) were treated with actinomycin D and total cellular RNA harvested
at 2 and 6 h. TF mRNA levels were measured by quantitative PCR. TF
mRNA half-life was not altered byTNF-a pretreatment.
Figure 4. Proteasome inhibitor MG-132 partially inhibits TNF-a-
mediated increases in TF protein expression. (A) Pretreatment of
HDMEC with MG132 (50 mM) partially inhibits TNF-a (1000 U per ml
 4 h) mediated induction of TF protein expression as measured by cell
ELISA. (B) Pretreatment of HDMEC with MG132 prior toTNF-a stimu-
lation completely inhibited TNF-a-mediated induction of E-selectin. Re-
sults shown are a single representative experiment.
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PD98059 resulted in inhibition of TNF-a-mediated increases in
TF hnRNA expression, suggesting that both agents inhibited TF
gene transcription.
DISCUSSION
TF expression in endothelial cells is potentially regulated via a
complex interplay of mechanisms, which may operate in a cell-
speci¢c fashion (Holschermann et al, 2001). Cytokine activation
may induce changes in cell surface expression of TF via changes
in gene transcription, mRNA stability, protein translation, or
protein tra⁄cking (Hansen et al, 2001). As has been observed in
large vessel derived EC, HDMEC express TF after treatment
with the proin£ammatory cytokine TNF-a, and increased cell
surface expression of TF is associated with increases in steady-
state mRNA levels and TF gene transcription. In HDMEC, TF
is an early immediate gene whose transcription does not require
new protein translation. TNF-a treatment did not greatly a¡ect
mRNA stability, suggesting that the primary e¡ect of cytokine
treatment is on TF gene transcription.
The signaling pathways involved inTF induction in HDMEC
appear to be distinct from those observed previously in large ves-
sel EC models such as HUVEC. In contrast to previous studies
describing MEK1/p44/42 MAPK-dependent upregulation of TF
in HUVEC (Mechtcheriakova et al, 2001), our data clearly de-
monstrate that TNF-a-mediated increases of TF in HDMEC are
mediated via an MEK1-independent pathway. The speci¢c
MEK1 inhibitor PD98059 had no signi¢cant e¡ect on TNF-
a-mediated TF upregulation in HDEMC. A demonstrable
PD98059 e¡ect that was clearly shown by blockade of both con-
stitutive and TNF-a augmented expression of phospho-p44/42
and signi¢cant inhibition of TF expression in HUVEC.
In contrast, pretreatment of either HDMEC or HUVEC with
either the p38 MAPK inhibitors SB203580, or the proteasome in-
hibitor MG132 blocked TF induction by TNF-a. Our data sug-
gest that the target for p38 MAPK inhibitor and MG-132 e¡ect
is on TF gene transcription as both SB203580 and MG132 pre-
treatment had profound e¡ects on TNF-a-mediated increases in
TF gene transcription as measured by induction of hnRNA.
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
Figure 5. Inhibition of p38 MAPK, but not MEK1 inhibits TNF-a-
mediated induction of TF in HDMEC. Pretreatment of HDMECwith
PD98059 (50 mM) did not inhibit TNF-a (1000 U per ml  4 h) mediated
TF induction (B). Pretreatment of HDMEC with SB203580 (10 mM) (a) or
SB202190 (10 mM) (E) resulted in 4 80% inhibition of TNF-a-mediated
TF induction. Pretreatment of HDMEC with SB203580 (10 mM) (C) or
PD98059 (50 mM) (D) prior to TNF-a stimulation did not a¡ect TNF-a-
mediated induction of E-selectin. PD98059, MG-132, SB203580 blocked
TNF-a-mediated TF induction in HUVEC (F). Cell surface expression of
TF was measured by cell ELISA. HDMEC and HUVEC were pretreated
with PD98059 (50 mM) or SB203580 (10 mM) prior to TNF-a stimulation
(1000 U per ml  10 min). HDMEC were harvested and examined by
western blot using antibodies speci¢c for p44/42 phospho-MAPK and
p44/42 MAPK (G).
Figure 6. MG132 and SB203580 inhibit TNF-a-mediated TF gene
transcription. HDMEC were pretreated with MG132 (50 mM) or SB
203580 (10 mM) prior to stimulation with TNF-a (1000 U per ml  2 h).
Total cellular RNA was harvested and levels of both TF mRNA and
hnRNAwere measured by quantitative PCR.
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The target for MG132 e¡ects is likely the NF-kB element in
the TF promoter. By inhibiting IkBa degradation, MG132 pre-
vents translocation of active NF-kB complexes from the cyto-
plasm to the nucleus, thus blocking TF gene transcription.
Despite marked inhibition of TF gene transcription, cell surface
expression of TF was more modestly a¡ected. The e¡ect of pro-
teasome inhibitors may be more complex than just e¡ects on NF-
kB activation.These agents also have e¡ects on protein tra⁄cking
and endosome function (van Kerkhof et al, 2001). It is possible
that proteasome inhibitors may also a¡ect TF protein tra⁄cking,
preventing TF protein internalization. Any inhibition of TF in-
ternalization may partially blunt any inhibitory e¡ects on TF
gene transcription, resulting in greater cell surface expression
than what might be predicted from observed mRNA levels.
The target for SB203580 is not entirely de¢ned. SB203580 did
not mediate its e¡ects via inhibition of MEK1, as SB203580 actu-
ally augmented p44/42 phosphorylation. It is possible that
SB203580 has e¡ects on NF-kB activation, but this is extremely
unlikely as SB203580 pretreatment had limited e¡ects on E-selec-
tin induction, an NF-kB dependent gene that is profoundly
sensitive to proteasome inhibitors. It is also possible that phos-
phorylation of AP-1 binding proteins such as fos or jun may be
critical for binding and/or transactivation of the TF gene in
HDMEC as has been suggested in HUVEC (Mackman, 1996,
1997). In addition, p38 MAPK may be important for regulating
mRNA stability. The 30 tail of TF mRNA contains AUUUA
motifs that have been associated with labile mRNA species,
whose stability can be regulated via a p38 MAPK-dependent me-
chanism (Winzen et al, 1999). Finally, recently work has identi¢ed
selected TNF-a regulated genes that are dependent upon p38
MAPK-mediated histone modi¢cation for transcription (Winzen
et al, 1999). It is possible that NFkB sequences required for TF
gene expression are unpackaged via a p38 MAPK-dependent
mechanism.
The distinct mechanisms regulating TF expression in skin
microvascular endothelial cells are intriguing but not entirely
unexpected. We have previously shown microvascular speci¢c
expression of both constitutive and inducible proteins, including
CD36 and vascular cell adhesion molecule-1 (Swerlick et al,
1992a,b). Furthermore, cell-speci¢c regulation of TF has been
previously demonstrated with contrasting patterns of regulation
in monocytes and large vessel endothelial cells (Holschermann
et al, 2001). The fact that endothelial cells derived from di¡erent
elements of the vascular tree regulate TF via distinct mechanisms
is consistent with the regulatory diversity already recognized. It is
possible that some di¡erences may be due to contamination of
cultures with lymphatic derived endothelial cells as has been pre-
viously described (Kriehuber et al, 2001).We have found that evi-
dence of podoplanin mRNA in cultures of HDMEC and not
HUVEC, suggesting some level of contamination with lympha-
tic endothelial cells (unpublished observations).Whatever that le-
vel of contamination might turn out to be, our observations of a
single population by £ow cytometry of TF expressing cells fol-
lowingTNF-a stimulation would suggest that there are no major
di¡erences in the regulation of TF between lymphatic and blood
vessel derived endothelial cells. De¢nitive studies will require
studies on de¢ned populations of endothelial cells and will be
possible when appropriate reagents become widely available.
Given the importance of TF as a regulator of coagulation cascade,
these observations potentially have interesting implications in
explaining localization of thrombosis to vessels of di¡erent
types and/or calibers. Di¡erences in regulatory pathways may
ultimately allow for organ or vessel type speci¢c regulation of
endothelial-mediated clotting functions.
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